NascaCell Technologies AG
NascaCell Technologies AG receives US Patent to generate Microbodies
NascaCell Technologies AG / Miscellaneous Release of a Corporate-announcement, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Munich, Germany, April 3, 2007 – The US Patent Office has granted NascaCell patent US 7,186,524 B2: 'Method for exposing peptides and polypeptides on the cell surface of bacteria'. This method allows the selection and identification of binding entities against interesting target molecules from large MicrobodyTM libraries. With this proprietary process, NascaCell can generate peptides and MicrobodiesTM free of Third Party patents. The technology was developed by Prof. H. Kolmar and colleagues at the Georg-August University, Göttingen. In 2006, NascaCell acquired the technology from the University of Göttingen via its technology transfer organization MBM ScienceBridge GmbH. About NascaCell Technologies AG – www.nascacell.com NascaCell Technologies AG, based in Munich, is a global leading provider of a new generation of biomolecules. With the innovative Aptamer and MicrobodyTM technologies, the company supports customers in the target validation and drug discovery R&D areas. NascaCell also develops a line of products and drug development candidates based on the Microbody™ technology. Contact: InvestorPress GmbH Georg Breu Phone: +49(0)89 55 96 98 75 info@investorpress.de DGAP 03.04.2007 ----------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found